Turnstone Logo.jpg
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber
October 30, 2023 06:00 ET | Turnstone Biologics Corp.
Internationally recognized cancer immunotherapy thought leader, Dr. Weber, will help guide Turnstone’s continued advancement of its Selected TIL therapies
Turnstone Logo.jpg
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 28, 2023 06:00 ET | Turnstone Biologics Corp.
Turnstone Biologics to present preclinical data for its Selected TILs at SITC's 38th Annual Meeting.
Turnstone Logo.jpg
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update
September 01, 2023 17:57 ET | Turnstone Biologics Corp.
Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programsCash position expected to fund operations into second quarter of...
Turnstone Logo.jpg
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering
July 21, 2023 02:15 ET | Turnstone Biologics Corp.
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure...
Nurix.png
Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting
April 08, 2022 13:02 ET | Nurix Therapeutics, Inc.
Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide drug (IMiD) activity of NX-2127, resulting in robust tumor cell killing Animal...
Nurix.png
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
November 12, 2021 07:09 ET | Nurix Therapeutics, Inc.
Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial Phase 1 clinical trial initiation anticipated by year-end 2021 SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) --...
Nurix.png
Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference
November 12, 2021 07:07 ET | Nurix Therapeutics, Inc.
DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL Michael T. Lotze, Nurix’s chief cellular...
Reports and Data.jpeg-01
T-Cell Therapy Market To Reach USD 8.37 Billion By 2027 | Reports and Data
February 19, 2020 14:00 ET | Reports and Data
New York, Feb. 19, 2020 (GLOBE NEWSWIRE) -- The Global T-Cell Therapy Market is forecast to reach USD 8.37 Billion by 2027, according to a new report by Reports and Data. The T-cell therapy involves...